Literature DB >> 29130141

Sjögren's syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review.

Xiaohan Xu1, Tienan Zhu2, Di Wu3, Lu Zhang4.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a potentially lethal multisystem disorder which could be caused by autoimmune diseases. However, the concomitant occurrence of TTP and Sjögren's syndrome (SS) is an extremely uncommon scenario, especially in male patients. A 56-year-old Chinese male was admitted for the appearance of diffuse ecchymosis. Then he gradually developed transient slurred speech, progressive confusion, agitation, extremity weakness, and fever. Laboratory investigations suggested anemia, thrombocytopenia, significantly increased lactic dehydrogenase, schistocytes in peripheral blood smear, and a disintegrin-like metalloproteinase with thrombospondin motif type 1 member 13 (ADAMTS13) activity deficiency with high inhibitor titers. TTP was thus diagnosed. The patient also had positive anti-nuclear antibody, anti-SSA, and anti-SSB; however, anti-double stranded DNA (dsDNA) was negative. These drove us to perform ocular and dental sicca evaluation and the finial diagnosis was TTP secondary to SS. Plasma exchange and corticosteroid therapy were effective to control TTP. Cyclophosphamide was subsequently added when the platelet count was stable. The total duration of corticosteroid and cyclophosphamide was 8 and 6 months, respectively. The patient recovered without relapse at 1-year follow-up. To our knowledge, this was the first case of SS initially presented as TTP in a male patient. The case also elucidated the importance of autoantibody screen in the workup of TTP and the benefits of adjunctive immunosuppressive therapy in relapse prevention.

Entities:  

Keywords:  ADAMTS13; Cyclosporine; Sjögren’s syndrome; Thrombotic thrombocytopenic purpura

Mesh:

Substances:

Year:  2017        PMID: 29130141     DOI: 10.1007/s10067-017-3912-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  41 in total

Review 1.  Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.

Authors:  James N George
Journal:  Am J Hematol       Date:  2012-03-09       Impact factor: 10.047

2.  Oral cyclophosphamide for refractory or relapsing thrombotic thrombocytopenic purpura (TTP)

Authors:  M S Hertzberg; J Koutts
Journal:  Aust N Z J Med       Date:  1997-08

Review 3.  The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Wendy Lim; Sara K Vesely; James N George
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

4.  Androgens and integrins in salivary glands in Sjogren's syndrome.

Authors:  Pauliina Porola; Mikael Laine; Ismo Virtanen; Raimo Pöllänen; Beata D Przybyla; Yrjö T Konttinen
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

5.  Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2016-04-08       Impact factor: 22.113

6.  Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

Review 7.  Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.

Authors:  Boris Shenkman; Yulia Einav
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

Review 8.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

9.  Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.

Authors:  Eric Mariotte; Elie Azoulay; Lionel Galicier; Eric Rondeau; Fouzia Zouiti; Pierre Boisseau; Pascale Poullin; Emmanuel de Maistre; François Provôt; Yahsou Delmas; Pierre Perez; Ygal Benhamou; Alain Stepanian; Paul Coppo; Agnès Veyradier
Journal:  Lancet Haematol       Date:  2016-04-16       Impact factor: 18.959

Review 10.  The influence of sex steroids on Sjögren's syndrome.

Authors:  Pauliina Porola; Mikael Laine; Liisa Virkki; Praseet Poduval; Yrjö T Konttinen
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

View more
  1 in total

1.  Pregnancy-associated thrombotic thrombocytopenic purpura complicated by Sjögren's syndrome and non-neutralising antibodies to ADAMTS13: a case report.

Authors:  Lu Zhou; Yu Zhu; Miao Jiang; Min Su; Hong Liu; Jian Su; Xiaofan Liu; Yizhi Jiang; Hui Mu; Jie Yin; Li Yang; Haiyan Liu; Weidong Pan
Journal:  BMC Pregnancy Childbirth       Date:  2021-12-03       Impact factor: 3.007

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.